Chantal Burnison: BIOCHEMIST AND INVENTOR

Chantal Burnison is COO of BCS Pharma Corporation a subsidiary of the Singaporean conglomerate BCS Business Consulting Services Pte Ltd. Her path towards becoming COO and inventing one of the most medically endorsed and revolutionary cosmetic lines began when she attended UCLA at the age of 16. Intent on a career in academic medicine, she conducted research targeted for the pharmaceutical industry parallel to her university neuro and biochemistry studies. Observing his daughter to be of inventor profile, her father, the inventor of the pneumatic air nail gun, persuaded Chantal to divert from a profession in medicine to that of law and the pharmaceutical industry. With his financial backing, and after receiving her doctorate in law, Chantal Burnison pursued the research, development, patent acquisition and FDA approvals of several of her medically published breakthrough compounds, including her designed class ( X-Andron) of novel, safe and efficacious nonsteroidal anti-androgens (Cyoctol and Ethocyn). The anti-androgen molecular structures modulate intercellular DHT receptor binding. After years of safety and efficacy testing worldwide, the Cyoctol compounds are in their Phase II and III Clinical Trials, to date proving to safely and effectively treat numerous DHT mediated medical disorders, including acne vulgaris, hirsuitism, androgenetic alopecia, keloid scars ; and the Ethocyn compounds are confirmed (p<.001) to increase oneís important skin fibroblast cellsí elastin production in men and women over 25 years of age.

Ethocyn SKIN CARE PRODUCTS

The first commercially available X-Andron compound is Ethocyn, the unique ingredient featured in the Chantal Ethocyn Skin Treatment Products. Ethocynís safety and efficacy are the subject of medical publications and both US and international press coverage. Ethocyn is the only ingredient recognized by dermatologists and plastic surgeons to increase the important elastin fiber (skin's rubberbands) in men and women over 30 years of age to the elastin fiber percent found in young skin (20 year old). For more information visit www.ethocyn.com

Ethocyn Publications

1.  Methods for Documentation of Claims for Ethocyn in the Treatment of Aging Skin

2.  Percutaneous absorption, disposition, metabolism, and excretion of 14C-Labelled Cyoctol in humans after a single dermal application

3.  Treatment of Androgenetic Alopecia with Cyoctol-A Topical Antiandrogen

4.  A New Method for Determination of Scalping Hair Counts using Computer image Processing and Analysis

5.  Protocol – Cosmetic Treatment of Aging of the Skin with Topical Ethocyn – Pilot Study

6.  Dermal and Oral Developmental Toxicity Studies in Mice and Rabbits with the Antiandrogen, Cyoctol

7.  Topical Antiandrogens

8.  Ethocyn, a Cosmetic Treatment for Aging Skin

9.  Absorption, Distribution Metabolism and Excretion of 14Cyoctol in Human Volunteers

10.  Complete Metabolic Conversion of Cyoctol During Skin Passage After Dermal Application in Humans

11.  Richard A. Strick, M.D.  Report of Ethocyn Elastic Tissue Stimulation Three Month Dosing Study

12.  Differential Androgen Receptor Activity in Patients with Androgenic Alopecia and the Effects of Cyoctol on Dihydrotestosterone (DHT) Protein Binding

13.  Modulation of Connective Tissue Metabolism by Steroid Hormones and Ethocyn

14.  Increased Angrogen Binding in Keloids and its Inhibition with Cyoctol

15.  Dense Intraabdominal Adhesions- A Manifestation of Localized Hyper-Androgen Receptors

16.  Effects of Cyoctol vs. 13-CIS Retinoic Acid on Dihydrotestosterone (DHT) Receptor Binding in Human Facial Skin Fibroblasts

17.  Effects of Cyoctol vs. 13-CIS Retinoid Acid on Dihydrotestosterone Receptor Binding in Human Facial Sebaceous Glands

18.  Differential Androgen Receptor Activity in Patients with Androgenic Alopecia and the Effects of Cyoctol on Dihydrotestosterone (DHT) Protein Binding

19.  Increased Androgen Binding in Keloids:  A Preliminary Communication

 

products

CYoctol®
[6- (5-methoxyhept-1-yl) bicyclo [3.3.0] octan-3-one]
PATENTS
• Patents issued (racemate): Composition Matter; Process, Use
• Patents pending: (enantiomers/ isomers)
SAFETY
• PRECLINICAL: 5 species • C14 and H3 pharmacokinetic • acute toxicology • subacute toxicology • ADME • mutagenicity • carcinogenicity (2 yr) • teratology
• CLINICAL: Multicenter phase I-II univ clinical trials • hematology • urinalysis • serum chemistry • hormone assays • phototoxicity • irritation • allergenicity
EFFICACY
• PRECLINICAL: DHT-DHT receptor assays (K1) • Syrian hamster flank
• CLINICAL: [phase I-II multicenter univ. clinical trials]
-ACNE: Phase I • late Phase II
-ALOPECIA: Phase I • mid Phase II
-HIRSUITISM: Phase I • early Phase II
-KELOID: Phase I • early Phase II
Ethocyn®

[6- (5-ethoxyhept-1-yl) bicyclo [3.3.0] octan-3-one]
PATENTS
• Patents issued (racemate): Composition Matter; Process, Use
• Patents pending: (enantiomers/ isomers)
SAFETY
• PRECLINICAL: 5 species • C14 and H3 pharmacokinetic • acute toxicology • subacute toxicology • ADME • mutagenicity • carcinogenicity (2 yr) • teratology
• CLINICAL: Multicenter phase I-II univ clinical trials • hematology • urinalysis • serum chemistry • hormone assays • phototoxicity • irritation • allergenicity
EFFICACY
• PRECLINICAL: DHT-DHT receptor assays (K1) • Syrian hamster flank
• CLINICAL: [phase I-II multicenter univ. clinical trials] quantatative elastin fiber 2mm punch biopsies • bid, topical application • physician & patient eval.

Read more here or visit ethocyn.com for more information.   

Copyright chantal 2009